INCY – Incyte Corporation
INCY — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
5.61
Margin Of Safety %
23
Put/Call OI Ratio
0.63
EPS Next Q Diff
0.32
EPS Last/This Y
0.82
EPS This/Next Y
1.24
Price
93.7
Target Price
109
Analyst Recom
2.41
Performance Q
-7.96
Upside
139.1%
Beta
0.85
Ticker: INCY
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | INCY | 97.34 | 0.72 | 0.25 | 17060 |
| 2026-03-10 | INCY | 96 | 0.72 | 0.15 | 17024 |
| 2026-03-11 | INCY | 94.64 | 0.72 | 1.46 | 17039 |
| 2026-03-12 | INCY | 92.04 | 0.72 | 0.37 | 17098 |
| 2026-03-13 | INCY | 92.03 | 0.72 | 0.60 | 17098 |
| 2026-03-17 | INCY | 94.2 | 0.73 | 1.90 | 17099 |
| 2026-03-18 | INCY | 92.23 | 0.74 | 1.65 | 17174 |
| 2026-03-19 | INCY | 92.91 | 0.72 | 0.12 | 16995 |
| 2026-03-20 | INCY | 90.54 | 0.70 | 0.49 | 16929 |
| 2026-03-23 | INCY | 90.46 | 0.70 | 0.20 | 10218 |
| 2026-03-24 | INCY | 90.62 | 0.70 | 0.04 | 10268 |
| 2026-03-25 | INCY | 92.24 | 0.67 | 0.98 | 10539 |
| 2026-03-26 | INCY | 92.29 | 0.67 | 0.01 | 10897 |
| 2026-03-27 | INCY | 90.32 | 0.68 | 0.05 | 10809 |
| 2026-03-30 | INCY | 90.61 | 0.68 | 0.25 | 10835 |
| 2026-03-31 | INCY | 94.16 | 0.68 | 0.07 | 10835 |
| 2026-04-01 | INCY | 94.29 | 0.68 | 0.12 | 10883 |
| 2026-04-02 | INCY | 95.94 | 0.67 | 0.02 | 10922 |
| 2026-04-06 | INCY | 94.87 | 0.63 | 1.08 | 11329 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-09 | INCY | 97.10 | 21.4 | 3.2 | 7.42 |
| 2026-03-10 | INCY | 96.00 | 21.4 | -43.9 | 7.42 |
| 2026-03-11 | INCY | 94.63 | 21.4 | -51.1 | 7.42 |
| 2026-03-12 | INCY | 92.03 | 21.4 | -78.3 | 7.42 |
| 2026-03-13 | INCY | 92.52 | 21.4 | -11.0 | 7.42 |
| 2026-03-17 | INCY | 94.21 | 21.4 | 4.6 | 7.42 |
| 2026-03-18 | INCY | 92.23 | 20.2 | -64.7 | 7.44 |
| 2026-03-19 | INCY | 92.92 | 20.2 | -19.2 | 7.44 |
| 2026-03-20 | INCY | 90.78 | 18.3 | -79.9 | 7.43 |
| 2026-03-23 | INCY | 90.46 | 18.3 | -41.6 | 7.43 |
| 2026-03-24 | INCY | 90.62 | 18.3 | -30.4 | 7.43 |
| 2026-03-25 | INCY | 92.23 | 19.5 | 1.4 | 7.43 |
| 2026-03-26 | INCY | 92.29 | 19.5 | -33.1 | 7.43 |
| 2026-03-27 | INCY | 90.32 | 19.5 | -77.3 | 7.43 |
| 2026-03-30 | INCY | 90.35 | 19.2 | -33.6 | 7.41 |
| 2026-03-31 | INCY | 94.12 | 19.2 | 51.2 | 7.41 |
| 2026-04-01 | INCY | 94.28 | 19.2 | -31.0 | 7.41 |
| 2026-04-02 | INCY | 95.92 | 19.2 | 0.6 | 7.41 |
| 2026-04-06 | INCY | 94.86 | 19.2 | -56.6 | 7.41 |
| 2026-04-07 | INCY | 93.70 | 19.2 | -59.0 | 7.41 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-09 | INCY | -14.13 | 0.91 | 5.59 |
| 2026-03-10 | INCY | -14.13 | 0.91 | 5.59 |
| 2026-03-11 | INCY | -14.13 | 0.91 | 5.59 |
| 2026-03-12 | INCY | -14.13 | 0.91 | 5.59 |
| 2026-03-13 | INCY | -14.13 | 0.91 | 5.59 |
| 2026-03-17 | INCY | -14.13 | 0.96 | 5.59 |
| 2026-03-18 | INCY | -14.13 | 0.96 | 5.59 |
| 2026-03-19 | INCY | -14.79 | 0.96 | 5.59 |
| 2026-03-20 | INCY | -14.79 | 0.96 | 5.59 |
| 2026-03-23 | INCY | -14.79 | 0.96 | 5.59 |
| 2026-03-24 | INCY | -14.79 | 0.96 | 5.59 |
| 2026-03-25 | INCY | -14.79 | 0.96 | 5.61 |
| 2026-03-26 | INCY | -14.79 | 0.96 | 5.61 |
| 2026-03-27 | INCY | -14.79 | 0.96 | 5.61 |
| 2026-03-30 | INCY | -14.79 | 0.96 | 5.61 |
| 2026-03-31 | INCY | -14.79 | 0.96 | 5.61 |
| 2026-04-01 | INCY | -14.79 | 0.96 | 5.61 |
| 2026-04-02 | INCY | -14.79 | 0.96 | 5.61 |
| 2026-04-06 | INCY | -14.79 | 0.98 | 5.61 |
| 2026-04-07 | INCY | -14.65 | 0.98 | 5.61 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
1.46
Avg. EPS Est. Current Quarter
1.38
Avg. EPS Est. Next Quarter
1.78
Insider Transactions
-14.65
Institutional Transactions
0.98
Beta
0.85
Average Sales Estimate Current Quarter
1233
Average Sales Estimate Next Quarter
1361
Fair Value
115.63
Quality Score
100
Growth Score
96
Sentiment Score
92
Actual DrawDown %
16.6
Max Drawdown 5-Year %
-41.5
Target Price
109
P/E
14.63
Forward P/E
10.48
PEG
0.9
P/S
3.63
P/B
3.6
P/Free Cash Flow
13.76
EPS
6.4
Average EPS Est. Cur. Y
7.41
EPS Next Y. (Est.)
8.65
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
25.03
Relative Volume
0.77
Return on Equity vs Sector %
-2.6
Return on Equity vs Industry %
14
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
-59
◆
INCY
Healthcare
$93.69
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
47
Range 1M
52.2%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
8.4%
EPS NY
21.3%
52W%
68.4%
Long-Term Value
Quality companies, undervalued
WATCH
🟢 BUY
+121.8% upside
Upside
+121.8%
Quality
100
MoS
23%
Incyte CorporationSector: Healthcare
Industry: Biotechnology
Employees: 2844
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
INCY
Latest News
—
Caricamento notizie per INCY…
stock quote shares INCY – Incyte Corporation Stock Price stock today
news today INCY – Incyte Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch INCY – Incyte Corporation yahoo finance google finance
stock history INCY – Incyte Corporation invest stock market
stock prices INCY premarket after hours
ticker INCY fair value insiders trading